AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Ophthalmology Market by Segment, Disease, Drug Class, and Region - Outlook to 2025 - ResearchAndMarkets.com

May 23, 2019

DUBLIN--(BUSINESS WIRE)--May 23, 2019--

The “Global Ophthalmology Market by Segment, Disease, Drug Class, and Region - Outlook to 2025” report has been added to ResearchAndMarkets.com’s offering.

Treatment paradigm of eye disorders primarily aims to reduce inflammation, repairs traumatic injuries, and improves or saves eyesight. Treatment comprises of medication, surgery, prescription glasses or contact lenses and treatment of systemic conditions affecting the eye. Prevalence of eye disorders has been increasing incessantly. This is expected to boost the global ophthalmic market.

Furthermore, other factors such as rising R&D in the industry, growing geriatric population, and increasing awareness are also expected to drive growth. However, the market faces various challenges due to the high cost of diagnosis & treatment, patent expiration of blockbuster ophthalmic drugs and limited insurance coverage.

The report provides in-depth analysis of the current scenario, detailed market outlook of the global ophthalmology market with market segmentation across indications such as Retinal Disorder, Glaucoma & Dry Eye; drug classes such as - Anti Glaucoma Drugs, Dry Eye Drugs & Anti-infective Drugs.

Future forecasts of the ophthalmology market overall and across various market segments have been provided in the report until 2025. Furthermore, major industry players have been prudently analysed in the competitive landscape section of the report in order to provide key comparative insights.

Major industry players operating in the global ophthalmology market include Novartis AG, Bausch & Lomb, Inc., F.Hoffman La-Roche, Regeneron Pharmaceuticals, Inc., Allergan PLC, among others. These players are profiled herein based on attributes such as business overview, product segments, and financial analysis.

It also compiles the performance comparison of the aforementioned companies and other leading companies in the segment based on various parameters in the competitive landscape section.

In totality, the report provides detailed market analysis, with relevant forecasted data supported by key market dynamics. This information will be helpful in evaluating opportunities in the global ophthalmology market.

Key Vendors

Key Topics Covered

1. Executive Summary

2. Research Methodology

3. Ophthalmology
3.1 Background
3.2 Eye Disorders

4. Market Analysis
4.1 Market Sizing (Actual & Forecasted)
4.2 Market Share Analysis
4.2.1 Market Share by Segment
4.2.2 Market Share by Indication
4.2.3 Market Share by Drug Class
4.2.4 Market Share by Products
4.2.5 Market Share by Product Type
4.2.6 Market Share by Dosage Type
4.2.7 Market Share by Region

5. Market Segmentation
5.1 Segments
5.1.1 Surgical
5.1.1.1 Market Sizing (Actual & Forecasted)
5.1.1.2 Implantable Market Sizing (Actual & Forecasted)
5.1.1.3 Consumables Market Sizing (Actual & Forecasted)
5.1.1.4 Equipment/Others Market Sizing (Actual & Forecasted)
5.1.2 Vision Care
5.1.2.1 Market Sizing (Actual & Forecasted)
5.1.2.2 Contact Lenses Market Sizing (Actual & Forecasted)
5.2 Disease
5.2.1 Retinal Disorder
5.2.1.1 Market Sizing (Actual & Forecasted)
5.2.1.2 Market Share by Disease Type
5.2.1.3 nAMD Market Sizing (Actual & Forecasted)
5.2.1.4 DME/DR Market Sizing (Actual & Forecasted)
5.2.2 Glaucoma
5.2.2.1 Market Sizing (Actual & Forecasted)
5.2.3 Dry Eye
5.2.3.1 Market Sizing (Actual & Forecasted)
5.3 Drug Class
5.3.1 Anti-Glaucoma Drugs
5.3.2 Dry Eye Drugs
5.3.3 Anti-Infective Drugs

6. Regional Analysis
6.1 North America
6.2 Europe
6.3 Asia Pacific

7. Market Dynamics
7.1 Industry Trends & Development
7.1.1 Mergers & Acquisitions
7.1.2 Advent of Novel Drug Delivery Techniques
7.2 Growth Drivers
7.2.1 Prevalence of Eye Disorder
7.2.3 Rising R&D in the Industry
7.2.4 Growing Geriatric Population
7.2.5 Increasing Awareness
7.3 Challenges
7.3.1 High Cost of Diagnosis & Treatment
7.3.2 Patent Expiration of Blockbuster Ophthalmic Drugs
7.3.3 Limited Insurance Coverage

8. Competitive Landscape
8.1 Market Share Analysis
8.2 Financial Analysis

9. Company Profiles
9.1 Novartis AG
9.2 Bausch & Lomb Inc.
9.3 F.Hoffman La-Roche
9.4 Regeneron Pharmaceuticals Inc.
9.5 Allergan PLC

For more information about this report visit https://www.researchandmarkets.com/r/2o1lcd

View source version on businesswire.com:https://www.businesswire.com/news/home/20190523005485/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Optical Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH OPTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 05/23/2019 10:25 AM/DISC: 05/23/2019 10:25 AM

http://www.businesswire.com/news/home/20190523005485/en